-
Preventing Declines in Cardiovascular Health From Childhood: Never Too Early for Heart Health. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-18 Natalie A Cameron,Norrina B Allen
-
Potassium Nitrate in Heart Failure With Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-18 Payman Zamani, Sanjiv J. Shah, Jordana B. Cohen, Manyun Zhao, Wei Yang, Jessica L. Afable, Maria Caturla, Hannah Maynard, Bianca Pourmussa, Cassandra Demastus, Ipsita Mohanty, Michelle Menon Miyake, Srinath Adusumalli, Kenneth B. Margulies, Stuart B. Prenner, David C. Poole, Neil Wilson, Ravinder Reddy, Raymond R. Townsend, Harry Ischiropoulos, Thomas P. Cappola, Julio A. Chirinos
ImportanceNitric oxide deficiency may contribute to exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). Prior pilot studies have shown improvements in exercise tolerance with single-dose and short-term inorganic nitrate administration.ObjectiveTo assess the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants
-
Trajectory of Cardiovascular Health Across Childhood and Adolescence JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-18 Izzuddin M. Aris, Sheryl L. Rifas-Shiman, Wei Perng, Li Yi, Sarah D. de Ferranti, Marie-France Hivert, Emily Oken
ImportanceThe American Heart Association put forth the Life’s Essential 8 construct to assess cardiovascular health (CVH) based on 8 behavioral and health factors. Few studies have characterized the natural history of CVH in early life or identified its sociodemographic determinants.ObjectiveTo characterize CVH trajectories across childhood and adolescence and identify associations with sociodemographic
-
Chest Pain in a Middle-Aged Man JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-18 Qinghua Chang, Zhaolong Xu, Renguang Liu
A man in his mid-50s presented with chest pain lasting 30 minutes. The initial electrocardiogram showed type A preexcitation syndrome, with obvious ST-segment depression in leads V3 through V5 and positive delta wave. What would you do next?
-
Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-11 Pratyaksh K. Srivastava, Alexandra M. Klomhaus, Stephen J. Greene, Paul Heidenreich, Sabra C. Lewsey, Clyde W. Yancy, Gregg C. Fonarow
ImportanceAngiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.ObjectiveTo describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.Design, Setting, and ParticipantsUsing data from the Get With The Guidelines–Heart Failure (GWTG-HF)
-
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-11 Márton Kolossváry, Samuel R. Schnittman, Markella V. Zanni, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Gerald S. Bloomfield, Carlos D. Malvestutto, Judith Currier, Marissa R. Diggs, Christopher deFilippi, Allison Ross Eckard, Adrian Curran, Murat Centinbas, Ruslan Sadreyev, Borek Foldyna, Thomas Mayrhofer, Julia Karady, Jana Taron, Sara McCallum, Michael T. Lu, Heather J. Ribaudo, Pamela
ImportanceIn a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.ObjectiveTo use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond
-
-
Aspirin for Secondary Prevention of Atherosclerosis-Evidence or Dogma? JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-04 John G F Cleland
-
Unfolding the Link Between Transthyretin Stability and Survival. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-04 Anthony Angueira,Sarah A Abramowitz,Michael G Levin
-
Transthyretin Tetramer Destabilization and Increased Mortality in the General Population JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-04 Mette Christoffersen, Anders Møller Greve, Louise Stig Hornstrup, Ruth Frikke-Schmidt, Børge Grønne Nordestgaard, Anne Tybjærg-Hansen
ImportanceTransthyretin tetramer destabilization is the rate-limiting step in the development of transthyretin cardiac amyloidosis, an underrecognized contributor to mortality in older adults.ObjectiveTo test the hypothesis that transthyretin tetramer destabilization is associated with all-cause and cardiovascular mortality in the general population.Design, Setting, and ParticipantsIn this cohort study
-
Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-27 Jeehoon Kang, Jaewook Chung, Kyung Woo Park, Jang-Whan Bae, Huijin Lee, Doyeon Hwang, Han-Mo Yang, Kyoo-Rok Han, Keon-Woong Moon, Ung Kim, Moo-Yong Rhee, Doo-Il Kim, Song-Yi Kim, Sung-Yun Lee, Seung Uk Lee, Sang-Wook Kim, Seok Yeon Kim, Jung-Kyu Han, Eun-Seok Shin, Bon-Kwon Koo, Hyo-Soo Kim
ImportanceAntiplatelet monotherapy in the chronic maintenance period for patients with high bleeding risk (HBR) and those who have undergone complex percutaneous coronary intervention (PCI) has not yet been explored.ObjectiveTo compare clopidogrel vs aspirin monotherapy in patients with HBR and/or PCI complexity.Design, Setting, and ParticipantsThis post hoc analysis of the multicenter HOST-EXAM Extended
-
Alternative LDL Cholesterol–Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-20 Yong-Joon Lee, Bum-Kee Hong, Kyeong Ho Yun, Woong Chol Kang, Soon Jun Hong, Sang-Hyup Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
ImportanceIn patients with atherosclerotic cardiovascular disease (ASCVD), intensive lowering of low-density lipoprotein (LDL) cholesterol levels with high-intensity statins is generally recommended. However, alternative approaches considering statin-related adverse effects and intolerance are needed.ObjectiveTo compare the long-term efficacy and safety of an alternative LDL cholesterol–lowering strategy
-
Palpitations After Transcatheter Atrial Septal Defect Closure. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-20 Goran Medimurec,Željko Ðuric,Irena Ivanac Vranešic
-
Semaglutide Eligibility Across All Current Indications for US Adults JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-18 Ivy Shi, Sadiya S. Khan, Robert W. Yeh, Jennifer E. Ho, Issa J. Dahabreh, Dhruv S. Kazi
This cross-sectional study uses National Health and Nutrition Examination Survey data to examine the number of US adults eligible for semaglutide across all current indications.
-
Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-18 Mohammad Abdel Jawad, John A. Spertus, Uchechukwu Ikeaba, Stephen J. Greene, Gregg C. Fonarow, Karen Chiswell, Paul S. Chan
ImportanceSodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
-
The Fine Art and Science of Translating Trials Results Into Clinical Practice. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Gregg C Fonarow,Eric D Peterson,Adrian F Hernandez
-
Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Sadiya Khan,Clyde W Yancy,Gregg C Fonarow
-
Power of Digital Nudges to Boost Influenza Vaccination Rates. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Mohammad Madjid,Payam Safavi-Naeini
-
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Orly Vardeny, Muthiah Vaduganathan, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S. P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Shingo Matsumoto, Béla Merkely, Shelley Zieroth, Mehmet Birhan Yilmaz, James Lay-Flurrie, Prabhakar Viswanathan, Andrea Horvat-Broecker, Andrea Scalise, John J. V. McMurray, Scott D. Solomon
ImportanceTreatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), improved outcomes in patients with heart failure with mildly reduced or preserved ejection fraction in FINEARTS-HF, but was associated with increased levels of serum potassium in follow-up.ObjectiveTo investigate the frequency and predictors of serum potassium level greater than 5.5 mmol/L and less than
-
Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Ziang Yang, Xieraili Tiemuerniyazi, Fei Xu, Yang Wang, Yang Sun, Peng Yan, Liangxin Tian, Chao Han, Yan Zhang, Shiwei Pan, Zhan Hu, Xi Li, Wei Zhao, Wei Feng
ImportanceEfficient approaches to prevent postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) are still needed.ObjectiveTo investigate whether partial cardiac denervation, achieved by cutting off the ligament of Marshall (LOM) and resecting the fat pad along the Waterston groove, can reduce the risk of POAF following CABG.Design, Setting and ParticipantsThis single-center
-
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Misato Chimura, Xiaowen Wang, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Cândida Fonseca, Eva Goncalvesova, Tzvetana Katova, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Savina Nodari, Carolyn S. P. Lam, Clara Inés Saldarriaga, Michele Senni, Kavita Sharma, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Orly Vardeny, Muthiah Vaduganathan
ImportanceSex is associated with the clinical presentation, outcomes, and response to treatment in patients with heart failure (HF). However, little is known about the safety and efficacy of treatment with finerenone according to sex.ObjectiveTo estimate the efficacy and safety of finerenone compared with placebo in both women and men.Design, Setting, and ParticipantsPrespecified analyses were conducted
-
Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Adam Ioannou, Yousuf Razvi, Aldostefano Porcari, Muhammad U. Rauf, Ana Martinez-Naharro, Lucia Venneri, Salsabeel Kazi, Ali Pasyar, Carina M. Luxhøj, Aviva Petrie, William Moody, Richard P. Steeds, Brett W. Sperry, Ronald M. Witteles, Carol Whelan, Ashutosh Wechalekar, Helen Lachmann, Philip N. Hawkins, Scott D. Solomon, Julian D. Gillmore, Marianna Fontana
ImportanceTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of changes in kidney function over time has yet to be defined.ObjectiveTo assess the prognostic importance of a decline in estimated glomerular filtration rate (eGFR)
-
Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Ankeet S. Bhatt, Niklas Dyrby Johansen, Muthiah Vaduganathan, Daniel Modin, Manan Pareek, Safia Chatur, Brian L. Claggett, Kira Hyldekær Janstrup, Carsten Schade Larsen, Lykke Larsen, Lothar Wiese, Michael Dalager-Pedersen, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Rebecca C. Harris, Lars Køber, Scott D. Solomon, Cyril Jean-Marie Martel, Pradeesh Sivapalan, Jens Ulrik Stæhr Jensen, Tor
ImportanceInfluenza vaccination in patients with acute myocardial infarction (AMI) reduces major adverse cardiac events and is strongly recommended in clinical practice guidelines. Effective strategies to improve vaccination are needed in these high-risk patients.ObjectiveTo evaluate whether electronically delivered behavioral nudges improve influenza vaccine uptake in patients with AMI across 3 nationwide
-
Heart Failure in Zero Gravity—External Constraint and Cardiac Hemodynamics JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-16 James P. MacNamara, Christopher M. Hearon, Giorgio Manferdelli, Aman M. Shah, Kevin G. Tayon, Ambarish Pandey, Satyam Sarma, Benjamin D. Levine
In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.
-
Interpreting Health Status Measures in Patients With Heart Failure-What Counts. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-15 James E Udelson,Clyde W Yancy,Gregg C Fonarow
-
Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-15 Mohammad Abdel Jawad, Philip G. Jones, Suzanne V. Arnold, David J. Cohen, Charles F. Sherrod, Mirza S. Khan, Nobuhiro Ikemura, Paul S. Chan, John A. Spertus
ImportanceThe Kansas City Cardiomyopathy Questionnaire (KCCQ) is a commonly used outcome in heart failure trials. While comparing means between treatment groups improves statistical power, mean treatment effects do not necessarily reflect the clinical benefit experienced by individual patients.ObjectiveTo evaluate the association between mean KCCQ treatment effects and the proportions of patients experiencing
-
Emergency Medical Service Agency Cardiac Arrest Practices-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-13 Saket Girotra,Paul S Chan
-
Emergency Medical Service Agency Cardiac Arrest Practices. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-13 Henry E Wang
-
Bidirectional Risk Modulator and Modifier Variant of Dilated and Hypertrophic Cardiomyopathy in BAG3 JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-13 Joseph Park, Michael G. Levin, David Zhang, Nosheen Reza, Jonathan O. Mead, Eric D. Carruth, Melissa A. Kelly, Alex Winters, Colleen M. Kripke, Renae L. Judy, Scott M. Damrauer, Anjali T. Owens, Lisa Bastarache, Anurag Verma, Daniel D. Kinnamon, Ray E. Hershberger, Marylyn D. Ritchie, Daniel J. Rader
ImportanceThe genetic factors that modulate the reduced penetrance and variable expressivity of heritable dilated cardiomyopathy (DCM) are largely unknown. BAG3 genetic variants have been implicated in both DCM and hypertrophic cardiomyopathy (HCM), nominating BAG3 as a gene that harbors potential modifier variants in DCM.ObjectiveTo interrogate the clinical traits and diseases associated with BAG3
-
Distinct Genetic Risk Profile in Aortic Stenosis Compared With Coronary Artery Disease. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-06 Teresa Trenkwalder,Carlo Maj,Baravan Al-Kassou,Radoslaw Debiec,Stefanie A Doppler,Muntaser D Musameh,Christopher P Nelson,Pouria Dasmeh,Sandeep Grover,Katharina Knoll,Joonas Naamanka,Ify R Mordi,Peter S Braund,Martina Dreßen,Harald Lahm,Felix Wirth,Stephan Baldus,Malte Kelm,Moritz von Scheidt,Johannes Krefting,David Ellinghaus,Aeron M Small,Gina M Peloso,Pradeep Natarajan,George Thanassoulis,James
Importance Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist. However, it is unknown which genetic and cardiovascular risk factors might be AS-specific and which could be shared between AS and CAD. Objective To identify genetic risk loci and cardiovascular risk factors with AS-specific associations. Design, Setting, and Participants This was a genomewide association study (GWAS)
-
Heart Failure With Preserved Ejection Fraction-A Role for Invasive Hemodynamics. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-06 Gregg C Fonarow,James E Udelson,Clyde W Yancy
-
The Role of Fat in Frailty Assessment Before Transcatheter Aortic Valve Replacement. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-06 Alberto Somaschini,Amanda Casirati
-
Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-06 Jwan A. Naser, Tomonari Harada, Yogesh N. Reddy, Sorin V. Pislaru, Hector I. Michelena, Christopher G. Scott, Austin M. Kennedy, Patricia A. Pellikka, Vuyisile T. Nkomo, Mackram F. Eleid, Barry A. Borlaug
ImportanceSecondary tricuspid regurgitation (STR) is observed in multiple cardiac and pulmonary diseases. Heart failure with preserved ejection fraction (HFpEF) is a common cause of STR that may be overlooked, along with precapillary etiologies of pulmonary hypertension (PH).ObjectivesTo investigate the prevalence of HFpEF and precapillary PH in patients with severe STR of undefined etiology (isolated
-
Disease Drivers in Aortic Stenosis vs Atherosclerosis. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-06 Mark C Blaser,Elena Aikawa
-
Measuring Health Status in Patients With Tricuspid Regurgitation. JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-30 Eldrin F Lewis
-
TAVR in Young Patients With Aortic Stenosis: Appropriate Use or Indication Creep? JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-30 Robert O Bonow,Patrick T O'Gara
-
Outcomes of Balloon-Expandable Transcatheter Aortic Valve Replacement in Younger Patients in the Low-Risk Era JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-30 Megan Coylewright, Kendra J. Grubb, Suzanne V. Arnold, Wayne Batchelor, Abhijeet Dhoble, Aaron Horne, Martin B. Leon, Vinod Thourani, Tamim M. Nazif, Brian R. Lindman, Molly Szerlip
ImportanceGuidelines advise heart team assessment for all patients with aortic stenosis, with surgical aortic valve replacement recommended for patients younger than 65 years or with a life expectancy greater than 20 years. If bioprosthetic valves are selected, repeat procedures may be needed given limited durability of tissue valves; however, younger patients with aortic stenosis may have major comorbidities
-
Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-30 Suzanne V. Arnold, John A. Spertus, Kensey Gosch, Shannon M. Dunlay, Danielle M. Olds, Philip G. Jones, Fraser D. Bocell, Changfu Wu, David J. Cohen
ImportanceImproving patients’ health status is a key goal of treating tricuspid regurgitation (TR). The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure disease-specific health status measure used to capture the health status impact of TR and the benefit of transcatheter tricuspid valve intervention (TTVI), but its validity in this clinical setting is unknown.ObjectiveTo evaluate
-
Cerebral Embolic Protection by Geographic Region JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-29 Raj R. Makkar, Aakriti Gupta, Thomas E. Waggoner, Samuel Horr, Juhana Karha, Lowell Satler, Robert C. Stoler, Jorge Alvarez, Rahul Sakhuja, Lee MacDonald, Rodrigo Modolo, Martin B. Leon, Axel Linke, Samir R. Kapadia
ImportanceTranscatheter aortic valve replacement (TAVR) is an established treatment option for many patients with severe symptomatic aortic stenosis; however, debris dislodged during the procedure can cause embolic stroke. The Sentinel cerebral embolic protection (CEP) device is approved for capture and removal of embolic material during TAVR but its efficacy has been debated.ObjectiveTo explore regional
-
Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-27 Nanna Louise Junker Udesen,Rasmus Paulin Beske,Christian Hassager,Lisette Okkels Jensen,Hans Eiskjær,Norman Mangner,Amin Polzin,P Christian Schulze,Carsten Skurk,Peter Nordbeck,Peter Clemmensen,Vasileios Panoulas,Sebastian Zimmer,Andreas Schäfer,Nikos Werner,Martin Frydland,Lene Holmvang,Jesper Kjærgaard,Thomas Engstøm,Henrik Schmidt,Anders Junker,Christian Juhl Terkelsen,Steffen Christensen,Axel Linke
Importance Mechanical circulatory support with a microaxial flow pump (MAFP) has been shown to improve survival in ST-elevation myocardial infarction-induced cardiogenic shock (STEMI-CS). Understanding the impact on hemodynamic stability over time is crucial for optimizing patient treatment. Objective To determine if an MAFP reduces the need for pharmacological circulatory support without compromising
-
Evidence for Mechanical Circulatory Support in Cardiogenic Shock. JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-27 Jason E Bloom,Kais Hyasat,Ajay J Kirtane
-
Precision Medicine to Guide Blood Pressure Control? JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Sadiya S Khan
-
Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-23 Nicole D. Armstrong, Vinodh Srinivasasainagendra, Amit Patki, Alana C. Jones, Vibhu Parcha, Akhil Pampana, Ulrich Broeckel, Leslie A. Lange, Pankaj Arora, Nita A. Limdi, Hemant K. Tiwari, Marguerite R. Irvin
ImportanceThe clinical utility of polygenic risk scores (PRS) for blood pressure (BP) response to antihypertensive treatment (AHT) has not been elucidated.ObjectiveTo investigate the ability of a systolic BP (SBP) PRS to predict AHT response and apparent treatment-resistant hypertension (aTRH).Design, Setting, and ParticipantsThe Genetics of Hypertension Associated Treatments (GenHAT) study was an
-
Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Alexander Peikert,Scott D Solomon,Orly Vardeny
-
Age-Stratified Risk Categories for Cardiovascular Disease Prevention Therapies. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Cian P McCarthy,Kazem Rahimi,John W McEvoy
-
Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Alberto Donzelli
-
Parsing Signal vs Noise-Secondary Analyses of RCTs. JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-16 Gregg C Fonarow,Ajay J Kirtane,Clyde W Yancy
-
Aortic Stenosis, Heart Failure, and Aortic Valve Replacement JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-16 Siddhartha Mengi, James L. Januzzi, João L. Cavalcante, Marisa Avvedimento, Attilio Galhardo, Mathieu Bernier, Josep Rodés-Cabau
ImportanceHeart failure (HF) and aortic stenosis (AS) frequently coexist, presenting a complex clinical challenge due to their intertwined pathophysiology and associated high morbidity and mortality. Despite numerous advancements in transcatheter and surgical aortic valve replacement (AVR), HF decompensation remains the leading cause of cardiac rehospitalization and a major predictor of mortality in
-
Trends in Transcatheter Aortic Valve Replacement Outcomes JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-16 Suzanne V. Arnold, Pratik Manandhar, Sreekanth Vemulapalli, Andrzej S. Kosinski, Wayne B. Batchelor, Vinod H. Thourani, Michael J. Mack, David J. Cohen
ImportanceAlthough transcatheter aortic valve replacement (TAVR) outcomes in the US have improved substantially since 2011, it is unknown whether these trends have continued since 2019.ObjectiveTo examine changes in risk-adjusted TAVR outcomes from 2019 to 2022 and to examine any noteworthy trends over time.Design, Setting, and ParticipantsThis cohort study examined data from patients with severe aortic
-
Coronary Revascularization Guided With Fractional Flow Reserve or Instantaneous Wave-Free Ratio: A 5-Year Follow-Up of the DEFINE FLAIR Randomized Clinical Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-16 Javier Escaned,Alejandro Travieso,Hakim-Moulay Dehbi,Sukhjinder S Nijjer,Sayan Sen,Ricardo Petraco,Manesh Patel,Patrick W Serruys,Justin Davies,
Importance The differences between the use of fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) in the long term are unknown. Objective To compare long-term outcomes of iFR- and FFR-based strategies to guide revascularization. Design, Setting, and Participants The DEFINE-FLAIR multicenter study randomized patients with coronary artery disease to use either iFR or FFR as a pressure
-
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-09 Pedro E. P. Carvalho, Douglas M. Gewehr, Bruno R. Nascimento, Lara Melo, Giullia Burkhardt, André Rivera, Marcelo A. P. Braga, Patricia O. Guimarães, Roxana Mehran, Stephan Windecker, Marco Valgimigli, Dominick J. Angiolillo, Deepak L. Bhatt, Yader Sandoval, Shao-Liang Chen, Gregg W. Stone, Renato D. Lopes
ImportanceThe optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate.ObjectivesTo analyze the efficacy and safety of DAPT strategies in patients with ACS using a bayesian network meta-analysis.Data SourcesMEDLINE, Embase, Cochrane, and LILACS databases were searched from inception
-
Ventricular Septal Rupture After ST-Segment Elevation Myocardial Infarction JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-09 Alex Melot, Pierre Groussin, Raphaël P. Martins
This case report describes a diagnosis of ventricular septal rupture in a patient in his 70s after ST-segment elevation myocardial infarction (STEMI) due to right coronary artery occlusion.
-
Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-09 Didier Tchétché, Roxana Mehran, Daniel J. Blackman, Ramzi F. Khalil, Helge Möllmann, Mohamed Abdel-Wahab, Walid Ben Ali, Paul D. Mahoney, Hendrik Ruge, Sabine Bleiziffer, Lang Lin, Molly Szerlip, Kendra J. Grubb, Isida Byku, Mayra Guerrero, Linda D. Gillam, Anna Sonia Petronio, Guilherme F. Attizzani, Wayne B. Batchelor, Hemal Gada, Toby Rogers, Joshua D. Rovin, Brian Whisenant, Stewart Benton, Blake
ImportanceHistorically, women with aortic stenosis have experienced worse outcomes and inadequate recognition compared to men, being both underdiagnosed and undertreated, while also facing underrepresentation in clinical trials.ObjectiveTo determine whether women with small aortic annuli undergoing transcatheter aortic valve replacement have better clinical and hemodynamic outcomes with a self-expanding
-
Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Simone Biscaglia,Andrea Erriquez,Gianluca Campo
-
Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Martino Martinelli-Filho,José A Marin-Neto,Mauricio Ibrahim Scanavacca,Angelo Amato Vincenzo de Paola,Paulo de Tarso Jorge Medeiros,Ruth Owen,Stuart J Pocock,Sergio Freitas de Siqueira,
Importance Over 10 000 people with Chagas disease experience sudden cardiac death (SCD) annually, mostly caused by ventricular fibrillation. Amiodarone hydrochloride and the implantable cardioverter-defibrillator (ICD) have been empirically used to prevent SCD in patients with chronic Chagas cardiomyopathy. Objective To test the hypothesis that ICD is more effective than amiodarone therapy for primary
-
Frailty in an Elderly Cohort With Myocardial Infarction and High Bleeding Risk. JAMA Cardiol. (IF 14.8) Pub Date : 2024-12-01 Ahthavan Narendren,Anoop N Koshy
-
Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-02 Marat Fudim, Barry A. Borlaug, Rajeev C. Mohan, Matthew J. Price, Peter Fail, Parag Goyal, Scott L. Hummel, Teona Zirakashvili, Tamaz Shaburishvili, Ravi B. Patel, Vivek Y. Reddy, Christopher D. Nielsen, Stanley J. Chetcuti, Devraj Sukul, Rajiv Gulati, Luke Kim, Keith Benzuly, Sumeet S. Mitter, Liviu Klein, Nir Uriel, Ralph S. Augostini, John E. Blair, Krishna Rocha-Singh, Daniel Burkhoff, Manesh R
ImportanceGreater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF).ObjectiveTo explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM).Design, Setting, and ParticipantsThis was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted
-
Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure JAMA Cardiol. (IF 14.8) Pub Date : 2024-10-02 Amber B. Tang, Boback Ziaeian, Javed Butler, Clyde W. Yancy, Gregg C. Fonarow
ImportanceGuideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated.ObjectiveTo assess the projected population-level benefit of optimal GDMT use globally among patients
-
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-30 Sanjiv J. Shah, Marzia Rigolli, Atefeh Javidialsaadi, Ravi B. Patel, Suhail Khadra, Parag Goyal, Sean Little, Omar Wever-Pinzon, Anjali Tiku Owens, Hicham Skali, Pankaj Arora, Scott D. Solomon
ImportancePatients with heart failure with preserved ejection fraction (HFpEF) who have left ventricular ejection fraction (LVEF) of 60% or greater have limited treatment options.ObjectiveTo examine the effects of cardiac myosin inhibition with mavacamten in patients with HFpEF with LVEF of 60% or greater.Design, Setting, and ParticipantsThe EMBARK-HFpEF trial was a phase 2a, open-label, single-arm
-
Estimated Long-Term Benefits of Finerenone in Heart Failure JAMA Cardiol. (IF 14.8) Pub Date : 2024-09-27 Muthiah Vaduganathan, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S. P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Maria Borentian, James Lay-Flurrie, Prabhakar Viswanathan, Friederike U. Behmenburg, John J. V. McMurray, Scott D. Solomon
ImportancePeople living with heart failure (HF) with mildly reduced or preserved ejection fraction have substantially curtailed life expectancy free from clinical events compared with their peers of comparable age. The nonsteroidal mineralocorticoid receptor antagonist, finerenone, was recently shown to reduce risks of cardiovascular events in this population over a median follow-up of 2.6 years; as